Key points are not available for this paper at this time.
As the demand for CAR T cell cancer therapy increases, several closed and automated production platforms are being deployed, and others are in development.This review provides a critical appraisal of these technologies that can be leveraged to scale and optimize the production of next generation CAR T cells.
Abou‐El‐Enein et al. (Tue,) studied this question.